GSK “Sincerely Apologizes” And Accepts Record $485 Million Fine For China Bribes
This article was originally published in PharmAsia News
The ticket has finally been handed out. Amid a record fine for bribery, GSK says that it remains fully committed to China.
You may also be interested in...
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.
The latest developments in a US Congressional draft bill to curb Chinese biotech operations in the US is separating contract manufacturing and research from gene sequencing service providers, which may give China's major contract players reasons to breathe easy.
Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.